WHAT IS ALREADY KNOWN ON THIS TOPIC
hypertrophy, fibrosis, diabetes
DISEASE, FIBROSIS, HYPERTROPHY, HYPERTROPHIC CARDIOMYOPATHY (HCM), DIABETES
Therapies targeting underlying disease mechanisms in hypertrophic cardiomyopathy (HCM) remain limited. Trientine is a highly selective copper II chelator that is associated with reduced left ventricular (LV) hypertrophy and fibrosis, and improved mitochondrial function and energy metabolism, in diabetes. In a pilot study in HCM, trientine was associated improvements in cardiac structure and function.